Redhill Biopharma - ADR

NASDAQ:RDHL   3:40:43 PM EDT
9.83
+0.15 (+1.55%)
Products

Redhill Biopharma Announces FDA Orphan Drug Designation For RHB-204 For The Treatment Of NTM Infections

Published: 10/14/2020 19:49 GMT
Redhill Biopharma Ltd (RDHL) - Redhill Biopharma Announces FDA Orphan Drug Designation for Rhb-204 for the Treatment of Ntm Infections.
Redhill Biopharma - Rhb-204 Phase 3 Study in Pulmonary Ntm Infections is Planned to Be Initiated in Coming Weeks.
Redhill Biopharma Ltd - Rhb-204 Phase 3 Study in Pulmonary Ntm Infections is Planned to Be Initiated in Coming Weeks.
Redhill Biopharma- Orphan Drug Designation Will Extend U.S. Potential Market Exclusivity to a Total of 12 Years.